09Sep 2023
Long‐term efficacy/safety of canakinumab in patients with tumor necrosis factor receptor‐associated periodic syndrome

Long‐term efficacy/safety of canakinumab in patients with tumor necrosis factor receptor‐associated periodic syndrome

In a comprehensive assessment, the CLUSTER study's 72-week open-label extension examined canakinumab's effectiveness, safety, and tolerability in tumor necrosis factor receptor‐associated periodic syndrome (TRAPS) patients. Patients received 150 or 300 mg of canakinumab every 4 or 8 weeks, with up-titration allowed. Results revealed that over 94% of patients achieved minimal or no disease activity, and most experienced minimal flares. Median CRP levels remained below 10 mg/L. No unexpected safety concerns emerged. This study demonstrates that long-term canakinumab treatment effectively controls TRAPS disease activity with low flare rates.

  • #general medicine

Like

Save

Share